COYA logo

COYA
Coya Therapeutics Inc

1,134
Mkt Cap
$95.47M
Volume
78,396.00
52W High
$7.75
52W Low
$3.71
PE Ratio
-3.39
COYA Fundamentals
Price
$4.23
Prev Close
$4.07
Open
$4.11
50D MA
$4.48
Beta
1.05
Avg. Volume
138,453.83
EPS (Annual)
-$1.27
P/B
1.98
Rev/Employee
$993,219.13
$50.21
Loading...
Loading...
News
all
press releases
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recomme...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·13d ago
News Placeholder
Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Friday...
MarketBeat·20d ago
News Placeholder
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research...
Business Wire·21d ago
News Placeholder
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...
Business Wire·28d ago
News Placeholder
What is HC Wainwright's Estimate for COYA Q1 Earnings?
Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Coya Therapeutics in a note issued to investors...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Monday...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research...
Business Wire·1mo ago
News Placeholder
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)
Chardan Capital restated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Monday...
MarketBeat·2mo ago
<
1
2
...
>

Latest COYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.